EW

SEC source: 0001225208-20-007340 · doc4.xml · derivative · entry 4

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,575

Underlying: Common Stock · 2,575 shares

Expires 2027-05-06

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-20-007340 · doc4.xml · derivative · entry 3

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock · 18,700 shares

Expires 2027-05-06

F2 · derivative.exercise_date: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-20-007340 · doc4.xml · nonDerivative · entry 1

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,013

F1 · shares: These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-20-007339 · doc4.xml · derivative · entry 3

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Common Stock · 2,000 shares

Expires 2027-05-06

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-20-007339 · doc4.xml · derivative · entry 2

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,600

Underlying: Common Stock · 14,600 shares

Expires 2027-05-06

F2 · derivative.exercise_date: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-20-007339 · doc4.xml · nonDerivative · entry 1

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,367.8898

F1 · shares: These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-20-007338 · doc4.xml · derivative · entry 3

Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,450

Underlying: Common Stock · 1,450 shares

Expires 2027-05-06

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-20-007338 · doc4.xml · derivative · entry 2

Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,600

Underlying: Common Stock · 10,600 shares

Expires 2027-05-06

F2 · derivative.exercise_date: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-20-007338 · doc4.xml · nonDerivative · entry 1

Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,684

F1 · shares: These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-20-007337 · doc4.xml · derivative · entry 8

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,025

Underlying: Common Stock · 2,025 shares

Expires 2027-05-06

F5 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F5 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F5 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F5 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F5 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-20-007337 · doc4.xml · derivative · entry 7

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,300

Underlying: Common Stock · 16,300 shares

Expires 2027-05-06

F4 · derivative.exercise_date: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

SEC source: 0001225208-20-007337 · doc4.xml · nonDerivative · entry 1

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,446.5169

F1 · shares: These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-20-007336 · doc4.xml · derivative · entry 12

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,825

Underlying: Common Stock · 8,825 shares

Expires 2027-05-06

F10 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F10 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F10 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F10 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F10 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-20-007336 · doc4.xml · derivative · entry 11

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,700

Underlying: Common Stock · 70,700 shares

Expires 2027-05-06

F9 · derivative.exercise_date: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

SEC source: 0001225208-20-007336 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,200.82

F1 · shares: These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-20-007361 · doc4.xml · nonDerivative · entry 4

GALLAHUE KIERAN · CIK 0001308428 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 17,471

SEC source: 0001225208-20-007361 · doc4.xml · nonDerivative · entry 1

GALLAHUE KIERAN · CIK 0001308428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001225208-20-006962 · doc4.xml · derivative · entry 4

Wood Larry L · CIK 0001440660 · CVP, TAVR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,970

Underlying: Common Stock · 3,566 shares

Expires 2022-05-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019.

SEC source: 0001225208-20-006962 · doc4.xml · nonDerivative · entry 2

Wood Larry L · CIK 0001440660 · CVP, TAVR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,535.9047

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019.

SEC source: 0001225208-20-006962 · doc4.xml · nonDerivative · entry 1

Wood Larry L · CIK 0001440660 · CVP, TAVR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,101.9047

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019.

SEC source: 0001225208-20-006929 · doc4.xml · nonDerivative · entry 1

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,767.8898

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020.

SEC source: 0001225208-20-006773 · doc4.xml · derivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,470 shares

Expires 2020-05-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2019.

SEC source: 0001225208-20-006773 · doc4.xml · nonDerivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,931.0477

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2019.

SEC source: 0001225208-20-006773 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,401.0477

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2019.

SEC source: 0001225208-20-006509 · doc4.xml · nonDerivative · entry 1

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,754.8898

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020.

SEC source: 0001225208-20-006422 · doc4.xml · derivative · entry 3

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,834

Underlying: Common Stock · 3,883 shares

Expires 2021-05-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020.

SEC source: 0001225208-20-006422 · doc4.xml · nonDerivative · entry 2

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,235.9256

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020.

SEC source: 0001225208-20-006422 · doc4.xml · nonDerivative · entry 1

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,146.9256

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020.

SEC source: 0001225208-20-006282 · doc4.xml · derivative · entry 17

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,850

Underlying: Common Stock · 32,850 shares

Expires 2020-05-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

SEC source: 0001225208-20-006282 · doc4.xml · nonDerivative · entry 15

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Living Trust

Disclosed balance after: 881,194

SEC source: 0001225208-20-006282 · doc4.xml · nonDerivative · entry 14

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,125.82

SEC source: 0001225208-20-006282 · doc4.xml · nonDerivative · entry 13

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,125.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F13 · price: This transaction was executed in multiple trades at prices ranging from $204.83 to $205.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-006282 · doc4.xml · nonDerivative · entry 12

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,525.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F12 · price: This transaction was executed in multiple trades at prices ranging from $203.81 to $204.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-006282 · doc4.xml · nonDerivative · entry 11

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,256.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F11 · price: This transaction was executed in multiple trades at prices ranging from $202.81 to $203.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-006282 · doc4.xml · nonDerivative · entry 10

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,755.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F10 · price: This transaction was executed in multiple trades at prices ranging from $200.79 to $201.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-006282 · doc4.xml · nonDerivative · entry 9

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,155.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F9 · price: This transaction was executed in multiple trades at prices ranging from $201.80 to $202.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-006282 · doc4.xml · nonDerivative · entry 8

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,455.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F8 · price: This transaction was executed in multiple trades at prices ranging from $198.71 to $199.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-006282 · doc4.xml · nonDerivative · entry 7

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,455.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F7 · price: This transaction was executed in multiple trades at prices ranging from $199.76 to $200.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-006282 · doc4.xml · nonDerivative · entry 6

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,755.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F6 · price: This transaction was executed in multiple trades at prices ranging from $195.735 to $196.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-006282 · doc4.xml · nonDerivative · entry 5

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,660.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F5 · price: This transaction was executed in multiple trades at prices ranging from $196.735 to $197.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-006282 · doc4.xml · nonDerivative · entry 4

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,460.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F4 · price: This transaction was executed in multiple trades at prices ranging from $205.84 to $206.415. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-006282 · doc4.xml · nonDerivative · entry 3

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,160.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F3 · price: This transaction was executed in multiple trades at prices ranging from $194.62 to $195.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-006282 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,575.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F2 · price: This transaction was executed in multiple trades at prices ranging from $197.45 to $197.655. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-006282 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,975.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

SEC source: 0001225208-20-006081 · doc4.xml · derivative · entry 6

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,372

Underlying: Common Stock · 5,369 shares

Expires 2020-05-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019.

SEC source: 0001225208-20-006081 · doc4.xml · nonDerivative · entry 2

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,821.5169

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019.

SEC source: 0001225208-20-006081 · doc4.xml · nonDerivative · entry 1

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,190.5169

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019.

SEC source: 0001225208-20-005798 · doc4.xml · derivative · entry 4

Wood Larry L · CIK 0001440660 · CVP, TAVR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,536

Underlying: Common Stock · 3,566 shares

Expires 2022-05-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019.

SEC source: 0001225208-20-005798 · doc4.xml · nonDerivative · entry 2

Wood Larry L · CIK 0001440660 · CVP, TAVR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,535.9047

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019.

SEC source: 0001225208-20-005798 · doc4.xml · nonDerivative · entry 1

Wood Larry L · CIK 0001440660 · CVP, TAVR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,101.9047

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019.